Skip to main content

Neuromuscular Training Cuts Onset of Chemo-Induced Peripheral Neuropathy

Medically reviewed by Carmen Pope, BPharm. Last updated on July 22, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, July 22, 2024 -- Neuromuscular training reduces the onset of chemotherapy-induced peripheral neuropathy (CIPN), according to a study published online July 1 in JAMA Internal Medicine.

Fiona Streckmann, Ph.D., from the University of Basel in Switzerland, and colleagues examined whether sensorimotor training (SMT) and whole-body vibration (WBV) training reduce symptoms and decrease onset of CIPN among patients undergoing treatment with oxaliplatin or vinca alkaloids. A total of 158 patients were randomly assigned into three groups: SMT (55 patients), WBV (53 patients), and treatment as usual (TAU; 50 patients).

The researchers found that the incidence of CIPN was significantly lower in SMT and WBV groups compared with TAU (30.0 and 41.2 percent, respectively, versus 70.6 percent) in intention-to-treat analysis. The most benefit was seen for patients receiving vinca alkaloids and performing SMT. In a per-protocol analysis, the results were more pronounced (28.6 and 37.5 percent, respectively, versus 73.3 percent). For balance control bipedal with eyes open, bipedal with eyes closed, monopedal, vibration sensitivity, sense of touch, lower leg strength, pain reduction, burning sensation, chemotherapy dose reductions, and mortality, improvements were seen in favor of SMT versus TAU.

"We were able to show that SMT can decrease CIPN, as well as maintain and improve subjective and objective outcomes, such as vibration sensitivity, sense of touch, lower leg strength, pain, burning sensation, and balance control," the authors write. "WBV showed a reduced incidence of CIPN and improved balance in a bipedal stance."

Two authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted July 2024

Read this next

Modifiable Risk Factors Account for Many Cancer Cases, Deaths

MONDAY, July 15, 2024 -- An estimated 40.0 percent of all incident cancer cases and 44.0 percent of cancer deaths are attributable to potentially modifiable risk factors among...

Mediterranean Diet Adherence Tied to Lower Mortality for Cancer Survivors

WEDNESDAY, July 10, 2024 -- For cancer survivors, higher adherence to a traditional Mediterranean diet (MD) is associated with a reduction in all-cause mortality, specifically...

Racial Differences Seen in Epigenetic Age Acceleration in Childhood Cancer Survivors

TUESDAY, July 9, 2024 -- For childhood cancer survivors, there are racial and ethnic disparities in epigenetic age acceleration (EAA), which are partially mediated by social...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.